跳至主要内容
临床试验/DRKS00003551
DRKS00003551招募中4 期

graft function adapted tacrolimus therapy after liver transplantation (GRAFTT) - GRAFTT

Charité Universitätsmedizin Berlin0 个研究点目标入组 210 人开始时间: 2013年5月31日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Inclusion criteria
  • -Patients intended for orthotopic deceased-
  • - Recipient age =18 yrs.
  • - Capability to understand the purpose and
  • the risk of the study
  • - Written informed consent prior LT

排除标准

  • - Participation in other clinical trials during <28 days before LT
  • - any organ transplantation before enrollment, High-urgent transplantation, split liver LT, living donor LT, combined multi-organ transplantation, AB0 incompatible grafts, retransplantation
  • - Recipients with malignant tumors beside HCC respecting the Milan criteria or liver metastasis
  • -Target trough levels of tacrolimus differing from 10-15 ng/mL in the first 14 days after LTx)
  • - planned use of other immunosuppressive drugs including ciclosporine A, sirolimus, everolimus, azathioprine in the first 14 days after LTx
  • - patients with known intolerance of tacrolimus
  • - patients with a history of substance or drug abuse
  • - patients with psychiatric disorders or any forms of substance abuse not capable of understanding the purpose and risks of the study
  • - subjects known to be HIV positive- pregnant woman or breastfeeding mother

研究者

相似试验